

AMENDMENT

Please amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

IN THE CLAIMS

Please amend the allowed claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Claims 1-15 (canceled)

--16. (previously presented) A liquid polymeric composition for controlled release of eprinomectin consisting essentially of:

- (a) 1 to 10% of eprinomectin;
- (b) 1 to 10% of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the eprinomectin is 1:1 or less and the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35; and
- (c) at least one lipophilic solvent or a mixture of hydrophilic and lipophilic solvents, wherein the volume ratio of the hydrophilic and lipophilic solvents is from about 80:20 to about 5:95.

17. (previously presented) The composition of claim 16 wherein the lipophilic solvent is triacetin.

18. (previously presented) The composition of claim 16 wherein the hydrophilic solvent is N-methyl pyrrolidone.

19. (previously presented) The composition of claim 17 wherein the hydrophilic solvent is N-methyl pyrrolidone.

20. (previously presented) The composition of claim 17 consisting essentially of:

- (a) 1 to 10% of eprinomectin;
- (b) 1 to 10% of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the eprinomectin is 1:1 or less

and the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35; and

(c) triacetin.

21. (currently amended) The composition of claim 19 consisting essentially of:

(a) 1 to 10% of eprinomectin;

(b) 1 to 10% of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the eprinomectin is 1:1 or less and the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35; and

(c) ~~triacetin~~ N-methyl pyrrolidone and ~~N-methyl pyrrolidone~~ triacetin, wherein the volume ratio of the ~~triacetin~~ N-methyl pyrrolidone and ~~N-methyl pyrrolidone~~ triacetin is from about 80:20 to about 5:95.

22. (previously presented) The composition of claim 20 wherein (a) consists essentially of about 5% eprinomectin.

23. (previously presented) The composition of claim 21 wherein (a) consists essentially of about 5% eprinomectin.

24. (previously presented) The composition of claim 22 wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is about 75:25.

25. (previously presented) The composition of claim 23 wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is about 75:25.

26. (previously presented) The composition of claim 24 wherein (b) is 5% poly(lactide-co-glycolide) copolymer.

27. (previously presented) The composition of claim 25 wherein (b) is 5% poly(lactide-co-glycolide) copolymer.

28. (previously presented) A method for the controlled release of eprinomectin in a mammal which comprises injecting said mammal with the composition of any one of claims 16-27.

29. (previously presented) The method of claim 28 wherein the mammal is a bovine.

30. (previously presented) The method of claim 28 wherein the mammal is an ovine.
31. (previously presented) The method of claim 28 wherein the mammal is a canine.--